Table 2 Expression of CLDN15 and other markers for MPM in three types of MPMs and lung adenocarcinoma tissues.
From: CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
CLDN15 | Calretinin | WT-1 | D2-40 | Total | ||
|---|---|---|---|---|---|---|
Epithelioid-type MPM | 26 (93%)** | 26 (93%)** | 14 (50%) | 24 (86%)* | 28 | |
Biphasic-type MPM | 6 (75%) | 6 (75%) | 5 (63%) | 6 (75%) | 8 | |
Sarcomatoid-type MPM | 3 (50%) | 2 (33%) | 2 (33%) | 4 (67%) | 6 | |
Total MPM | 35 (83%)* | 34 (81%)* | 21 (50%) | 34 (81%)* | 42 | |
Lung adenocarcinoma | 4/50 | 4/40 | 1/40 | 0/40 | ||
Specificity | 92% | 90% | 98% | 100% |
CL15 or Cal | CL15 or WT1 | CL15 or D2-40 | Cal or WT1 | Cal or D2-40 | WT1 or D2-40 | |
|---|---|---|---|---|---|---|
Epithelioid-type MPM | 28 (100%) | 27 (96%) | 28 (100%) | 27 (96%) | 27 (96%) | 26 (93%) |
Biphasic-type MPM | 7 (88%) | 7 (88%) | 7 (88%) | 7 (88%) | 8 (100%) | 8 (100%) |
Sarcomatoid-type MPM | 4 (67%) | 4 (67%) | 5 (83%) | 3 (50%) | 5 (83%) | 5 (83%) |
Total MPM | 39 (93%) | 38 (90%) | 40 (95%) | 37 (88%) | 40 (95%) | 39 (93%) |
Lung adenocarcinoma | 7/40 | 5/40 | 4/40 | 5/40 | 4/40 | 1/40 |
Specificity | 83% | 88% | 90% | 88% | 90% | 98% |
CL15 & Cal | CL15 & WT1 | CL15 & D2-40 | Cal & WT1 | Cal & D2-40 | WT1 & D2-40 | |
|---|---|---|---|---|---|---|
Epithelioid-type MPM | 24 (71%) | 13 (46%)† | 22 (79%) | 13 (46%)† | 23 (82%)‡ | 12 (43%)† |
Biphasic-type MPM | 5 (63%) | 4 (50%) | 5 (63%) | 4 (50%) | 4 (50%) | 3 (38%) |
Sarcomatoid-type MPM | 1 (17%) | 1 (17%) | 2 (33%) | 1 (17%) | 1 (17%) | 1 (17%) |
Total MPM | 30 (71%) | 18 (43%) | 29 (69%)‡ | 18 (43%) | 28 (67%) | 16 (38%)† |
Lung adenocarcinoma | 1/40 | 0/40 | 0/40 | 0/40 | 0/40 | 0/40 |
Specificity | 98% | 100% | 100% | 100% | 100% | 100% |
